We recently published a list of 10 Best Annual Dividend Stocks To Buy Now. In this article, we are going to take a look at ...

We recently compiled a list of the 10 Best Foreign Stocks With Dividends For Passive Income. In this article, we are going to ...

In a report released today, James Quigley from Goldman Sachs maintained a Hold rating on Novartis AG (NOVN – Research Report), with a price ...

Most readers would already be aware that Novartis' (VTX:NOVN) stock increased significantly by 7.9% over the past month.

Anthos Therapeutics is a clinical-stage biopharmaceutical company developing abelacimab, a potential first-in-class monoclonal antibody targeting the FXI inhibition pathwayAbelacimab is currently in P ...

Novartis AG is paying nearly $1 billion up front to buy privately held Anthos Therapeutics Inc. in a deal that eventually could top out around $3.1 billion. Novartis, coming back to where it started ...

Chicago Partners Investment Group LLC bought a new stake in shares of Novartis AG (NYSE:NVS – Free Report) during the 4th ...

Q4 2024 Earnings Call Transcript January 31, 2025 Novartis AG beats earnings expectations. Reported EPS is $1.98, ...

About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the ...

In a report released today, Eric Le Berrigaud from Stifel Nicolaus maintained a Hold rating on Novartis AG (NOVN – Research Report), with a ...

In his next chief executive gig after securing the $14 billion acquisition of Karuna Therapeutics Inc., Bill Meury has now locked in another big biotech deal.